Overview

Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)

Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
Selumetinib therapy in patients with metastatic uveal melanoma.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Dacarbazine